Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Clinical trial approval / initiation
InnoVec Biotherapeutics’ IVB102 Receives FDA IND Approval for X-Linked Retinoschisis Treatment
Beijing-based gene therapy specialist InnoVec Biotherapeutics Inc. has announced receiving Investigational New Drug (IND) approval...
HuidaGene Therapeutics Initiates HERO Trial for RNA-Editing Therapy HG204 in MECP2 Duplication Syndrome
Shanghai-based HuidaGene Therapeutics has announced the first subject dosing of the HERO clinical trial, which...
Simcere Pharmaceutical’s SIM0508 Reaches First Patient Dosing in Global Clinical Study
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the first patient...
Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received clinical clearance from...
Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial
Shanghai Juncell Therapeutics has announced that the National Medical Products Administration’s Center for Drug Evaluation...
Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials
China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has announced receiving clinical clearance...
HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors
Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...
Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral
US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...
CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia
China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...
Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC
Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National...
Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial...
Sichuan Kelun-Biotech’s SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, (HKG: 6990), a leading biopharmaceutical company based in China, has...
Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Guangzhou Virotech’s Oncolytic Virus M1 Receives Tacit Clinical Approval from NMPA
Guangzhou Virotech Pharmaceutical Co., Ltd., a China-based pharmaceutical company, has announced receiving tacit clinical approval...
OncoC4, Inc. Receives FDA Clearance for AI-081, a PD-1 and VEGF Bispecific Antibody
US-based OncoC4, Inc. has announced that it has received clinical clearance from the US Food...
Abbisko Therapeutics Gets FDA Green Light for Phase I Study of ABSK131 Inhibitor
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Zhejiang Huahai Pharmaceutical Initiates Clinical Study for HB0056 in New Zealand
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521), through its subsidiary Shanghai Huaota Biopharmaceutical Co., Ltd.,...
Ocumen Therapeutics’ OT-301 Phase III Denali Study Surpasses 140 Patient Enrollment in China
Chinese ophthalmology specialist Ocumen Therapeutics (HKG: 1477) has announced the enrollment of more than 140...
Simcere Zaiming Launches Phase III Trial for SERD Inhibitor SIM0270 in Breast Cancer
Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the initiation of a...